Pancreatic Cancer Research

ResearcherGold Coast HealthActive in the last 2 years

Andrew Oar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4723-7059; OpenAlex author ID A5049340497, A5159326673. Sources: ClinicalTrials.gov.

Their work

Papers
2
Trials
1
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2019: 1 trial · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

  1. Perioperative chemotherapy and stereotactic body radiotherapy versus perioperative chemotherapy alone in patients with high-risk, localised pancreatic cancer (… Co-author DOI 10.1016/s1470-2045(26)00532-2↗
  2. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk an… Co-author DOI 10.1186/s12885-021-08666-y↗

Trials 1

  1. MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease Study chair NCT04089150↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jaswinder Singh Samra · 2 shared papers, 2021–2026 · strength 0.30
  2. Andrew P. Barbour · 2 shared papers, 2021–2026 · strength 0.30
  3. David Paul Goldstein · 1 shared paper, 2026 · strength 0.20
  4. David Goldstein · 1 shared paper, 2021 · strength 0.10
  5. Val Gebski · 1 shared paper, 2021 · strength 0.10
  6. Nam Quoc Nguyen · 1 shared paper, 2021 · strength 0.10
  7. Lorraine A. Chantrill · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.